IceCure Medical Ltd cash flow to debt ratio of -6.72K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

IceCure Medical Ltd's free cash flow has decreased 15.64% from $-12.63M last year to $-14.61M, signaling decreasing performance

IceCure Medical Ltd's debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability.

IceCure Medical Ltd's debt has decreased relative to shareholder equity from 0.07 last year to 0.02 today, signaling strengthened financials

IceCure Medical Ltd has a net cash position, so leverage is healthy.

IceCure Medical Ltd earns at least as much interest as it pays. Interest obligations are fully covered.

IceCure Medical Ltd's profit margin has increased (-5.12%) in the last year from -465.45% to -441.60%, signaling increasing performance

IceCure Medical Ltd's short-term assets of $12.61M exceed its short-term liabilities of $4.82M

IceCure Medical Ltd's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

IceCure Medical Ltd's return on equity of -211.73%, is lower than 15.00%, indicating bad performance

IceCure Medical Ltd's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

IceCure Medical Ltd has insufficient public price history to evaluate earnings stability.

IceCure Medical Ltd has negative free cash flow, indicating the company is burning cash rather than generating it

IceCure Medical Ltd has negative free cash flow, indicating cash burn

IceCure Medical Ltd's yearly earnings has increased -1.70% since last year from $-15.32M to $-15.06M, signaling increasing performance

IceCure Medical Ltd's yearly revenue has increased 2.67% since last year from $3.29M to $3.38M, signaling increasing performance

ROIC -344.82% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

IceCure Medical Ltd's 3-year revenue CAGR of 3.08% is positive, indicating growing revenue over the past 3 years

IceCure Medical Ltd had revenue growth in 4 out of 5 years, indicating consistent revenue performance

IceCure Medical Ltd has insufficient public price history to evaluate ROE consistency.

IceCure Medical Ltd has insufficient data to evaluate this check.

IceCure Medical Ltd has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

IceCure Medical Ltd is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

IceCure Medical Ltd has negative or missing EBITDA, making EV/EBITDA ratio unreliable

IceCure Medical Ltd has insufficient data to evaluate this check.

IceCure Medical Ltd has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

IceCure Medical Ltd has a price-to-book ratio of 0.95x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

IceCure Medical Ltd has a price-to-sales ratio of 2.26x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue